Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Antidepressant Use Can Help Treat Major Depression During Perimenopause and Menopause

17.08.2010
Broadcast access to VCU experts can be arranged through the university’s VideoLink ReadyCam studio. ReadyCam transmits video and audio via fiber optics through a system that is routed to your newsroom. To schedule a live or taped interview, contact the VCU Office of Communications and Public Relations, 804-828-1231.

An antidepressant can alleviate symptoms of major depression in women experiencing or about to experience menopause, according to a study released today led by a Virginia Commonwealth University researcher.

The research compared the effectiveness and safety of the antidepressant desvenlafaxine, known as Pristiq, to a placebo in a double-blind trial led by Susan G. Kornstein, M.D., a professor of psychiatry and obstetrics/gynecology in the VCU School of Medicine. It was published in the Journal of Clinical Psychiatry.

In the United States, depression is approximately twice as common in women as in men. More than 20 percent of women will experience depression in the course of their lifetime, and depression seems to be influenced by reproductive events, such as the menstrual cycle, the postpartum period and menopause.

Research, including earlier work by Kornstein, has shown that women may respond to antidepressants differently from men and may also respond to medication differently at different times in their lives, she said.

“It’s really an assumption to say that because an antidepressant works for depression in general that it works for depression related to reproductive events,” she said. “This is the first large study testing the effectiveness of an antidepressant specifically in peri- and postmenopausal women with depression.”

Kornstein is an internationally recognized researcher in women’s mental health and depression at VCU who studies how depression affects women across their life span and the influence of the menstrual cycle and menopausal status on depression and its treatment.

Some women report mood swings, irritability, anxiety and depression in the years leading up to menopause, called the perimenopause. The reason for these emotional problems isn’t known, but the drop in estrogen levels that typically occurs during perimenopause and menopause may affect mood. The transition to menopause has been shown to be a high-risk period for major depression, in women both with and without a past history of depression.

In the new study, Kornstein and colleagues evaluated Pristiq’s ability to alleviate major depression among women experiencing or about to experience menopause. The study enrolled 387 women who were peri-or postmenopausal and were diagnosed with major depression at 37 outpatient sites across the country. The women were randomly assigned to take either 100 mg or 200 mg daily of Pristiq or placebo for eight weeks.

The study found that women who took Pristiq showed significant improvement as measured by the 17-item Hamilton Depression Rating Scale and other psychological tests. The response rates were 58.6 percent for those taking Prstiq, compared to 38.2 percent for those on placebo. The drug was effective among the subgroups of perimenopausal women as well as those who were postmenopausal.

At the time the study started, the federal Food and Drug Administration had not yet approved Pristiq, which patients now typically take in 50 mg daily doses to treat depression. Kornstein said she is about to start recruiting patients for a new, similar study using the 50 mg daily dose.

Pristiq works by increasing the amounts of serotonin and norepinephrine, natural substances in the brain that help maintain mental balance. It is manufactured by Pfizer and was approved in 2008 to treat depression among adults. Wyeth, now a subsidiary of Pfizer, financially supported the study.

Kornstein, a consultant for Pfizer, is co-founder and executive director of the VCU Mood Disorders Institute and of the VCU Institute for Women’s Health, a groundbreaking center for treatment, research, education, and community outreach. She is also medical director of the VCU Clinical Trials Office. Her co-authors from Pfizer were Qin Jiang; Sujana Reddy, M.D.; Jeff J. Musgnung; and Christine J. Guico-Pabia, M.D., MBA, MPH.

About VCU and the VCU Medical Center
Virginia Commonwealth University is a major, urban public research university with national and international rankings in sponsored research. Located on two downtown campuses in Richmond, VCU enrolls more than 32,000 students in 211 certificate and degree programs in the arts, sciences and humanities. Sixty-nine of the programs are unique in Virginia, many of them crossing the disciplines of VCU’s 13 schools and one college. MCV Hospitals and the health sciences schools of Virginia Commonwealth University compose the VCU Medical Center, one of the nation’s leading academic medical centers.

Sathya Achia Abraham | EurekAlert!
Further information:
http://www.vcu.edu

More articles from Health and Medicine:

nachricht Nanoparticles as a Solution against Antibiotic Resistance?
15.12.2017 | Friedrich-Schiller-Universität Jena

nachricht Plasmonic biosensors enable development of new easy-to-use health tests
14.12.2017 | Aalto University

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: First-of-its-kind chemical oscillator offers new level of molecular control

DNA molecules that follow specific instructions could offer more precise molecular control of synthetic chemical systems, a discovery that opens the door for engineers to create molecular machines with new and complex behaviors.

Researchers have created chemical amplifiers and a chemical oscillator using a systematic method that has the potential to embed sophisticated circuit...

Im Focus: Long-lived storage of a photonic qubit for worldwide teleportation

MPQ scientists achieve long storage times for photonic quantum bits which break the lower bound for direct teleportation in a global quantum network.

Concerning the development of quantum memories for the realization of global quantum networks, scientists of the Quantum Dynamics Division led by Professor...

Im Focus: Electromagnetic water cloak eliminates drag and wake

Detailed calculations show water cloaks are feasible with today's technology

Researchers have developed a water cloaking concept based on electromagnetic forces that could eliminate an object's wake, greatly reducing its drag while...

Im Focus: Scientists channel graphene to understand filtration and ion transport into cells

Tiny pores at a cell's entryway act as miniature bouncers, letting in some electrically charged atoms--ions--but blocking others. Operating as exquisitely sensitive filters, these "ion channels" play a critical role in biological functions such as muscle contraction and the firing of brain cells.

To rapidly transport the right ions through the cell membrane, the tiny channels rely on a complex interplay between the ions and surrounding molecules,...

Im Focus: Towards data storage at the single molecule level

The miniaturization of the current technology of storage media is hindered by fundamental limits of quantum mechanics. A new approach consists in using so-called spin-crossover molecules as the smallest possible storage unit. Similar to normal hard drives, these special molecules can save information via their magnetic state. A research team from Kiel University has now managed to successfully place a new class of spin-crossover molecules onto a surface and to improve the molecule’s storage capacity. The storage density of conventional hard drives could therefore theoretically be increased by more than one hundred fold. The study has been published in the scientific journal Nano Letters.

Over the past few years, the building blocks of storage media have gotten ever smaller. But further miniaturization of the current technology is hindered by...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

See, understand and experience the work of the future

11.12.2017 | Event News

Innovative strategies to tackle parasitic worms

08.12.2017 | Event News

AKL’18: The opportunities and challenges of digitalization in the laser industry

07.12.2017 | Event News

 
Latest News

Engineers program tiny robots to move, think like insects

15.12.2017 | Power and Electrical Engineering

One in 5 materials chemistry papers may be wrong, study suggests

15.12.2017 | Materials Sciences

New antbird species discovered in Peru by LSU ornithologists

15.12.2017 | Life Sciences

VideoLinks
B2B-VideoLinks
More VideoLinks >>>